FindTrial
Sign In

Assessment of Fatty Liver Disease in Obese Patients Using FibroScan: A Study on Its Prevalence

Estimation of the prevalence of metabolic dysfunction associated with steatotic liver disease using FibroScan in obese patients - NA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/05/111019
Enrollment
55
Registered
2026-05-25
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E669- Obesity, unspecified

Interventions

Intervention1: Nil: Nil

Sponsors

Datta Meghe Medical College, Wanadongri
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults greater than or equal to 18 years of age BMI greater than 30 kg per meter sq Willing to provide informed written consent No previously diagnosed chronic liver disease

Exclusion criteria

Exclusion criteria: Age less than 18 History of significant alcohol consumption (greater than 30 g/day in men, greater than 20 g/day in women, based on WHO AUDIT (Alcohol Use Disorders Identification Test) Known cases of: Viral hepatitis B or C Autoimmune hepatitis Wilson s disease, hemochromatosis Use of hepatotoxic drugs (methotrexate and amiodarone) Pregnancy or lactation Incomplete clinical records Refusal of informed consent

Design outcomes

Primary

MeasureTime frame
Prevalence of MASLD (defined as CAP score greater than or equal to 248 dB per meter on FibroScan) in obese adultsTimepoint: At the time of enrollment—

Secondary

MeasureTime frame
Steatosis grade distribution (S1 S3) Correlation of CAP score with metabolic syndrome parameters Timepoint: At the time of enrollment—

Countries

India

Contacts

Public ContactPrachi Sharma

DATTA MEGHE MEDICAL COLLEGE

bhauraonakhale55@gmail.com18001213333

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026